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Through epithelial-mesenchymal transition (EMT), cancer cells acquire enhanced ability of migration and invasion,
stem cell like characteristics and therapeutic resistance. Notch signaling regulates cell-cell connection, cell polarity
and motility during organ development. Recent studies demonstrate that Notch signaling plays an important role
in lung cancer initiation and cross-talks with several transcriptional factors to enhance EMT, contributing to the
progression of non-small cell lung cancer (NSCLC). Correspondingly, blocking of Notch signaling inhibits NSCLC
migration and tumor growth by reversing EMT. Clinical trials have showed promising effect in some cancer patients
received treatment with Notch1 inhibitor. This review attempts to provide an overview of the Notch signal in NSCLC:
its biological significance and therapeutic application.
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Lung cancer is a serious public health problem that af-
fects the lives of millions and is the most common cause of
cancer-related mortality [1]. Moreover, according to WHO
projections, the global burden of lung cancer is expected to
rise due to industrial and environmental pollution and
many other factors. In 2010, a report from National Central
Cancer Registry of China demonstrated that the lung can-
cer incidence and mortality increased to 46.08/100,000 and
37.00/100,000, respectively [2]. Non-small cell lung cancer
(NSCLC) accounts for approximately 80% of all lung can-
cers. NCI SEER database reported that 5-year survival was
58.2% for NSCLC patients diagnosed at localized stage
(18%) of all stages including localized, regional and distant
from 2004–2010, whereas it was only 4.5% when diagnosed
at distant stage (55%) [3]. Although many advances
achieved in cancer biology as well as in diagnosis and treat-
ment, progress in lung cancer therapy has been slow, lead-
ing to about 5% improvement in 5-year survival rates for
the last 20 years [4].* Correspondence: kmwu@tjh.tjmu.edu.cn
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oncogenic driver genes and therapies specific for these
genes or pathways. The common driver genes identified
so far in NSCLC included the mutant activations of
KRAS, EGFR, Met and BRAF [5]. In comparison with
standard chemotherapy, new target therapies show a sig-
nificant improved progression-free survival (PFS) and rela-
tively less toxicity [4]. However, the median PFS of
NSCLC patients with EGFR mutation was only 9.5
months on treatment with tyrosine kinase inhibitors
(TKIs) [6]; The median PFS for patients with locally ad-
vanced ALK-positive lung cancer was only 7.7 months
with crizotinib treatment [7]. Moreover, the overall sur-
vivals are not significantly improved for patients received
target therapy as compared with chemotherapy [6-8]. It is
obviously that overcoming refractory to target drugs can
prolong treatment response. In this respect, experimental
study proved that inhibition of hedhehog signaling abro-
gated resistance of NSCLC to TKI [9].
Novel inhibitors targeting multiple kinase sites are ex-
tensively developed, some have entered clinical trial. For
example, a novel kinase inhibitor targeting both EGFR
and HER2 has been evaluated in lung and breast cancer in
phase I study and is expected to bring improved responsed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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itional chemotherapeutics had also been deployed, such as
the conjunction of MEK inhibitors with anti-cancer drug
docetaxel in previously treated patients with advanced
lung cancer. Combined therapy revealed better response
rate and prolonged PFS than chemotherapy alone in a
phase II randomized trial [11].
In translational research, scientists performed compre-
hensive molecular studies to search for new genes in
lung cancer. Whole-genome and transcriptome sequen-
cing of tumor and adjacent normal tissue samples from
NSCLC had identified novel alterations in genes in-
volved in chromatin modification and DNA repair path-
ways, novel metabolic enzymes, as well as aberration of
cell fate determination factor DACH1 [12]. Further ex-
perimental study confirmed tumor suppresser function
of DACH1 in lung and other cancers [13,14]. Most re-
cent study to molecularly profile 230 resected adenocarcin-
omas revealed recurrent aberrations in multiple known
pathways and previously unknown mutations of RIT1 and
NF1 as new driver genes [15], suggesting the complexity of
NSCLC. Recently, novel genes or pathways involved in
tumor initiation and progression have been identified. For
instance, metastasis associated lung adenocarcinoma tran-
script 1 (MALAT1), a long non-coding RNA (lncRNA), has
been proven to function as a key regulator of brain metas-
tasis in NSCLC. By inhibiting epithelial-mesenchymal tran-
sition (EMT), silencing MALAT1 reduced lung cancer cell
invasion and metastasis. Clinically, protein abundance of
MALAT1 correlated tightly with the poor prognosis of pa-
tients [16]. Although many risk factors have been con-
nected tightly with the initiation and progression of
NSCLC, currently there is no satisfactory strategy that can
effectively prevent the cancer progression. Since extensive
invasion and remote metastases severely prevent the op-
tion of surgical intervention and are key causes for lung
cancer death, how to block those processes is always a
critical topic for basic research and clinic management.
Therapeutic refractory lung cancer cells frequently reveal
EMT phenotype and signaling to block EMT has been
shown to enhance chemotherapy sensitivity [17,18]. Taken
together, EMT, metastases and drug resistance are inter-
twined in NSCLC, which lead to aggravation and poor
prognosis. Therefore, more attention should be placed on
seeking potential pathways and new targets to improve
treatment outcome of NSCLC.
The role of EMT and CSCs in Metastasis of NSCLC
EMT is a highly coordinated process, in which epithelial
cells lose polarity together with cell-cell adhesion and
acquire properties of mesenchymal cells. Key transcrip-
tion factors driving EMT include the Snail homologues
(Snail1, Snail2/Slug and Snail3), twist, zinc finger E-box-
binding homeobox 1 (ZEB1) and ZEB2, and TCF3/E47/E12 [19,20]. Multiple signaling pathways, such as trans-
forming growth factor β (TGF-β), bone morphogenetic
protein (BMP), Wnt-β-catenin, Notch, Hedgehog, and re-
ceptor tyrosine kinases participate in this transition [21]
(Figure 1). In vitro studies have proved that TGF-β, integ-
rin and JAK/STAT3 signals caused EMT in lung adenocar-
cinoma cells [22-24]. The ability to invade and disseminate
of epithelial cells strongly relies on a dramatic remodeling
of the cytoskeleton, leading to the invasive properties in
promoting tumor metastasis accompanied with the acqui-
sition of mesenchymal phenotype [25]. E-cadherin, the
cadherin superfamily of Ca2+-dependent adhesion mole-
cules, plays a key role in the regulation of cell-cell interac-
tions [26]. Epigenetically silenced E-cadherin expression
was observed in advanced NSCLC and restoration of E-
cadherin expression strongly decreased the invasion/
migration of tumor cells [27]. In contrast, the up-
regulation of N-cadherin expression is linked to the me-
tastasis of NSCLC, whereas inhibition of N-cadherin was
demonstrated to reduce the proliferation and invasion of
NSCLC [28]. Additionally, the cell-cell communication
determines cell signaling, cell-cell interaction and cell
polarity. For example, the intercellular cell-adhesion
molecule-1 (ICAM-1), a transmembrane molecule and a
distinguished member of the immunoglobulin superfamily
of proteins, was involved in tumor invasion and EMT, and
was also correlated with tumor differentiation grade and
survival of NSCLC patient [29].
Via inducing translation suppression and mRNA deg-
radation, micro-RNAs serve as key administrators of post-
transcriptional regulation and also participate in EMT
[30]. More studies have proved that post-transcriptional
regulatory network, such as miR-200 family, miR-101,
miR-506, and several lncRNAs regulated EMT [31]. Hyp-
oxia is one of the fundamental biological phenomena that
is intricately associated with the development and aggres-
siveness of a variety of solid tumors. Multiple signaling
pathways such as NF-κB, PI3K/Akt/mTOR, Notch, Wnt/
β-catenin, and Hedgehog as well as hypoxia-induced
microRNAs (miRNAs) have been recognized as important
regulators of EMT in hypoxia environment, promoting
tumor progression [32,33].
The cancer stem cell (CSC) theory proposed that the ma-
lignant phenotype was sustained by a subset of cells charac-
terized by the capacity for self-renewal and differentiation.
It is believed that CSCs are responsible for propagating
growth, distant metastasis and recurrence [34]. Those cells
also enriched the expression of pluripotency genes and
epithelial-mesenchymal transition transcription factors,
along with reduced intercellular adhesion protein expres-
sion. However, the precise origin of lung CSCs is still not
clear [35]. Potential markers for identifying lung cancer
stem cells include CD133, CD44, ALDH, CD166 and
BMI. Analyses in multiple established and patient-derived
Figure 1 The signaling pathways in lung cancer. Oncogene activation or loss of tumor suppressor initiates lung tumor formation. The Notch,
Wnt and TGF-β signaling pathway are involved in the induction of EMT, CSCs and metastasis of NSCLC.
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ALDH(hi)CD44(hi) cells showed self-renewal, clono-
genicity, highly tumorigenic, high invasion capacities,
and resistance to chemotherapy [36]. Embryonic stem cell
pathways such as Notch, Hedgehog and WNT were found
active in lung cancers stem cells. Majority of human lung
adenocarcinoma samples demonstrated expression of SPC,
clara cell secretory protein (CCSP) and OCT4, characteris-
tics of bronchioalveolar stem cell(BASC) [37,38]. Experi-
ment demonstrated that in mouse and human airway basal
stem cells (ABSCs), activation of the Notch pathway was
required for ROS to stimulate ABSC self-renewal [39].
Altogether, EMT is frequently associated with stemness
property and therapeutic resistance, which contributes to
aggressive tumor growth, invasion and metastasis, and is
also recognized as the cause of tumor recurrence. In one
hand, the expressions of embryo stem cell related genes
are enriched on cells under EMT [38]. At the other hand,
knockdown of stem cell factor, Oct4/Nanog, suppressed
the expression of EMT gene Slug and reversed the EMT
process, followed by reduced tumorigenic and metastatic
ability. Importantly, survival time for mice bearing trans-
planted tumor double knockdown of Oct4/Nanog was
also greatly improved [40]. Moreover, the immunohisto-
chemical stain demonstrated expressions of Oct4, Nanog
and Slug were associated in high-grade human lung adne-
carcinoma tissues and the patients with triple positivity of
Oct4/Nanog/Slug indicated a worse prognosis [40].
The Notch signaling pathway in NSCLC
The Notch signaling is activated by ligand binding to re-
ceptor to initiate an intercellular communication system
[41]. There are five ligands, namely Delta-like 1, Delta-like 3,
Delta-like 4, Jagged-1 and Jagged-2, and four receptor
members (Notch 1 ~ 4). Ligand binding induces conform-
ational change in Notch, leading to the exposure of S2 site
for sequentially cleavage by a member of the A Disintegrin
And Metalloproteinase family of proteases and the gamma
secretase complex to liberates the Notch Intracellular
Domain (ICD), then ICD translocates to the nucleus [42].
In the nucleus, ICD binds with the transcription factorCBF-1/suppressor of hairless/Lag1 (CSL) and modu-
lates gene expression (Figure 2). Without ICD, CBF-1
protein binds to the consensus DNA sequence in associ-
ation with SMART complex, acting as a transcriptional
repressor. Interaction of CBF-1 with ICD displaces the co-
repressor SMART/HDACs complex, allowing for the tran-
scriptional activation of target genes, primarily involving in
two families of helix-loop-helix transcription factors: Hes
(Hairy enhance of split) and Hey (Hairy/enhancer of spit
related with YRPW motif) targeting genes. Other known
target genes include cyclinD1, c-myc, p21, p27, the nuclear
factor-kappa B (NF-κB), Survivin, Slug and Nanog [43].
Overwhelming evidence has proven that Notch signal-
ing is crucial for the development and homeostasis of
most tissues. Notch signaling has been known to partici-
pate in cell proliferation, differentiation and apoptosis.
Earlier studies discovered that deregulated Notch signaling
leads to various diseases, such as T cell leukemia and breast
cancer [44,45]. Notch1 mediates hypoxia-induced prolifer-
ation, invasion and chemoresistance [46]. Hypoxia also in-
duced CD133 expression, which has been used as a stem
cell biomarker of stem-like cells [47]. Subsequent study
demonstrated that Notch signaling drived stemness and
tumorigenicity of esophageal adenocarcinoma [48]. How-
ever, the effects of Notch signaling pathway on controlling
cell fates are cell- and tissue-type dependent. Notch activa-
tion in bladder cancer cells suppresses proliferation by re-
ducing the phosphorylation of ERK1 and ERK2 (ERK1/2).
In support of this, genetic inactivation of Notch signaling
in mouse models leads to Erk1/2 phosphorylation, result-
ing in tumorigenesis in the urinary tract [49].
The involvement of Notch on lung cancer was experi-
mentally proved in transgenic mouse model by the alveo-
lar epithelium specific expression of activated Notch [50].
The mice developed alveolar hyperplasias as early as
7 days’ induction of Notch and the lesions progressed to
pulmonary adenomas after 8 months’ induction. Molecu-
lar analyses revealed that Notch1 activation leads to dys-
regulated expansion of type II lung epithelial cells. When
crossed with mice conditionally overexpressing MYC in
the alveolar epithelium, mice developed adenocarcinomas.
Figure 2 Schematic representation of Notch signaling related to EMT. Upon ligand binding, Notch undergoes two proteolytic cleavages by
ADAM and γ-secretase complex, leading to the release of Notch-ICD and its translocating to the nucleus. In the nucleus Notch-ICD interacts with
CSL and activates numerous downstream target genes: upregulation of snail, slug, zeb1, cyclinD1 and Smad; downregultion of E-cadherin, p21,
etc. to induce EMT. (Notch-ECD, the extracellular domain of Notch; Notch-ICD, the intracellular domain of Notch; ADAM, a disintegrin and
metalloproteinase; CSL, CBF-1/suppressor of hairless/Lag1).
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man adenocarcinoma. Using an autochthonous model of
lung adenocarcinoma with concomitant expression of
oncogenic Kras and deletion of Notch1, Dr. Kissil’s group
found that Notch1 function was required for tumor initi-
ation via suppression of p53-mediated apoptosis through
the regulation of p53 stability [51]. Molecular analyses
defined subpopulation of CD24 (+) ITGB4 (+) Notch (hi)
cells were capable of propagating tumor growth in
both clonogenic and an orthotopic serial transplantation
assays. While all four Notch receptors represented tumor-
propagating cells, Notch3 plays a nonredundant role in
Kras models and in human NSCLC [52]. Interestingly, in
K-Ras mouse model, inhibition of Notch strongly in-
hibits adenocarcinoma formation but promotes squa-
mous hyperplasia in the alveoli. In contrast, activation
of Notch leads to widespread Sox2 (+), Sox9 (+), and
CC10 (+) papillary adenocarcinomas throughout the
bronchioles [53]. Those researches supported a strong and
direct role of Notch signaling in NSCLC. Other studies
had shown that under hypoxic conditions, Notch1 stimu-
lated NSCLC tumor growth through direct upregulation
of IGF1-R [54] and survivin [55], both of which enhanced
cell proliferation and survival.
In clinic study, activation of Notch signaling by either
Notch1 upregulation or Numb downregulation was ob-
served in 30% of primary human NSCLCs [56]. Notch3
also appears to be a key player in NSCLC, with overex-
pressed in 40% of NSCLC tumors [57]. In experimentalstudy, either dominant-negative Notch3 receptor [58] or
MRK-003, a gamma-secretase inhibitor [59], antagonized
Notch3 signaling, attenuated cell growth, and induced
apoptosis of lung cancer cell lines. In depth molecular
analyses demonstrated crosstalk between the Notch3 and
the EGFR pathway resulted in the inhibition of apoptosis
through expression of anti-apoptotic protein BIM [60].
For precise target therapy, the specific region within the
Notch3 extracellular domain with EGF receptor-like re-
peats was identified and that might be responsible for the
distinct effects of Notch3 versus those of Notch1. Func-
tional study showed peptides from these regions induced
apoptosis in NSCLC [61].
Clinically oriented studies have highlighted that Notch
signaling impacts survival in lung cancer patients. A re-
cent study by Donnem et al. assessed the prognostic im-
pact of Notch ligands and receptors in NSCLC and
found that high Notch1 expression was statistically signifi-
cantly associated with poor outcomes in lung adenocar-
cinoma [62]. Elevated levels of Notch-1, 3 and their ligand
Jagged 1–4 expressions were found to be associated with
tumor progression and predicted poor prognosis in
NSCLC, suggesting a promising biomarker for NSCLC
[62,63]. Delta-like ligand 4 and Notch-1 are independent
prognostic factors in NSCLC, but show diverse impacts
in squamous cell carcinoma and adenocarcinoma. In
addition, Jagged-1 was found to be highly expressed in
metastatic NSCLC compared to localized NSCLC [63].
The coexpression of Notch-1/VEGF-A has a major impact
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volved in the metastasis and determines the prognosis of
NSCLC.
Mechanism of Notch signaling in regulating EMT
Notch signaling pathway participates in an elaborate
gene program and protein network for the establishment
of motile and invasive mesenchymal phenotypes from polar-
ized epithelial properties, such as cell-cell connections and
cell polarity [64]. It was first revealed that Notch activity in-
duced EMT was required for cardiac valve and cushion for-
mation during heart development, involving down-
regulation of epithelial markers (E-cadherin) and up-
regulation of mesenchymal markers (snail) [65,66]. Mean-
while, inactivation of Notch signaling by a γ-secretase in-
hibitor could reverse the EMT process [67]. Interestingly,
over-expression of Jagged1 could trigger repression of E-
cadherin in human kidney epithelial cells, suggesting
Jagged-1 is a necessary element of Notch signaling for
promoting EMT [68]. In EMT processes, Notch cross-
talks with several transcription and growth factors rele-
vant to EMT, including Snail, Slug, TGF-β, FGF, and
PDGF [21,69]. Key targets in Notch signaling are dis-
cussed below.
Notch, Snail and E-cadeherin
Crystallization of Snail illustrates that it contains a con-
served carboxy-terminal region with 4-to 6-C2H2-zinc
fingers. By attaching through finger structures to E-box
motifs (5′-CANNTG-3′) in target promoters, such as
the E-cadherin gene (CDH1) promoter, Snail1 and Snail2
(Slug) act as transcriptional repressors [70]. The reduc-
tion of E-cadherin expression reduces the cell-cell junc-
tion and leads to destabilization of the epithelial structure,
which is an initial step in EMT. Experiments proved that
over-expression of Notch-ICD alone could increase snail
expression and resulted in the loss of E-cadherin. On the
contrary, inactivation of Notch attenuated the down-
regulation of E-cadherin expression and decreased Snail
expression, suggesting a direct role for Notch signaling via
Snail in the induction of EMT [71]. By recruitment of
hypoxia-inducible factors, HIF-1α and HIF-2α, Notch sig-
naling pathway could also increase Snail expression to
promote EMT through a sophisticated framework [72].
Interestingly, the inhibition of COX-2 could reverse the
ability of Notch1 to induce EMT, suggesting that Notch is
dependent on COX2 to mediate pro-metastasis via Snail/
E-cadherin in EMT [73]. Recent report from Dr. Pine’s
group indicates that Notch1 could regulate Sox9 expres-
sion through directly interaction with its promoter bind-
ing site to induce cell invasion and repress E-cadherin
[74]. It has also been demonstrated that Slug serves as an
activator in NSCLC cell lines during the induction of
EMT. Furthermore, inhibition of Notch signaling led topartial reversal of EMT by decreased expressions of Snail,
Slug, ZEB1, vimentin, and nuclear factor-kappaB, showing
slug was essential for Notch-mediated EMT [75]. These
findings linked Notch pathway and Snail/Slug tightly,
making them attractive targets for new therapeutics.
Notch and ZEB
ZEB family (ZEB1 and ZEB2), another group of tran-
scription factor, contributes to tumorigenicity as well as
EMT in NSCLC [76,77]. ZEB1 suppresses the expression
of cell polarity factors, in particular of Lgl2, which is crit-
ical for the epithelial phenotype and that its loss is in-
volved in metastasis [78]. Correspondingly, inhibition of
ZEB1 reverses EMT and chemo-resistance in docetaxel-
refract human lung adenocarcinoma cell line [79]. Im-
munohistochemical analyses of clinical sample revealed
that ZEB1 and twist are more commonly expressed in
metastatic than primary lung tumors and show inverse as-
sociations with claudins [80]. Subpopulation of metastasis-
prone mouse lung adenocarcinoma cells expresses high
level of Notch and Notch ligands, but decreased miR-200.
Reduction in Notch signaling resulted in reduced prolifer-
ation, increased apoptotic susceptibility, and decreased
tumorsphere formation [81]. It is concluded that inter-
action of Notch-miR-200-ZEB1 loop governed EMT and
metastatic capacity. This novel Notch/miR-200-dependent
pathway, which mediates lung adenocarcinoma metastasis
in mice, may provide new target for the treatment of hu-
man epithelial tumors.
Notch and TGF-β
The transforming growth factor beta (TGF-β), a ubiqui-
tous cytokine with profound growth inhibitory effects on
epithelial and other tissues, orchestrates an intricate sig-
naling network that is crucial to determine cell fate, dif-
ferentiation, proliferation and motile, leading to not only
tumour suppression but also EMT [82]. The TGF-β super-
family consists of the TGF-β family (TGF-β1, TGF-β2 and
TGF-β3), NODAL, activins, and bone morphogenetic pro-
teins (BMPs). Initiated by ligand-receptor binding, TGF-β
mediates the interaction of SMAD to the promoters of
Snail, contributing to the development of EMT in NSCLC
[83,84]. TGF-β induced EMT could be blocked by knock
down of Hey-1 or jagged-1 and by pharmacological inacti-
vation of Notch, indicating the key role of Notch signaling
in TGF-beta-induced EMT [85]. Meanwhile, inhibition of
Notch signaling could significantly inhibit TGF-β-induced
expression of SMA, suggesting Notch induced EMT
through a TGF-β-Smad3 pathway that activates SMA gene
transcription [86]. However, in cultured limbal progenitor
cells, Notch prevents TGF-β-assisted EMT through the in-
duction of Smad7 [87]. While in breast cancer, Notch
pathway inhibits TGF-β signaling through HEYL-mediated
crosstalk, promoting initiation of breast cancer [88].
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tween Notch signaling and TGF-β play a profound role in
EMT.
Notch and Cyclin D1
Hyper-activation of cyclins, especially the G1/S adminis-
trator cyclin D1 may favor tumor development by indu-
cing unscheduled cell division in progenitor cells [89].
The abundance of cyclin D1 has a significant relation-
ship with neoplastic progression of NSCLC [90,91]. In
epithelial ovary cancer cells, stem-like CD24- cells or spher-
oids highly expressed cyclin D1, Bmi-1, and vimentin with
reduced expression of E-cadherin, while non stem-like
CD24+ or parental cells showed the opposite expression.
Furthermore, cyclin D1-targeted small interfering RNA re-
sulted in decreased vimentin expression in spheroids, ac-
companying with reduced cell viability and migration [92].
In cervical squamous carcinoma, most invasive tumour
cells expressed cyclin D1 and showed a reduction in E-
cadherin and beta-catenin staining [93]. Epidermoid A431
cells expressing SIP1 along with exogenous cyclin D1 were
highly invasive, indicating that SIP1-regulated invasion is
independent of attenuation of G1/S progression [94]. Con-
versely, knock down Notch-3 reduced cyclin D1 with re-
duced proliferation and enhanced apoptosis [95]. Given the
importance of Notch and cyclin D1 in tumorigenesis, it is
not surprising that Notch pathway would participate in
regulation of cyclin D1-mediated EMT. Activation of Notch
signaling during neural induction in the ES cells led to sig-
nificantly enhanced cell proliferation, accompanied by
Notch-mediated activation of cyclin D1 expression. A re-
duction of cyclin-D1-expressing cells was observed in the
developing CNS of Notch signaling-deficient mouse em-
bryos. Moreover, expression of a dominant negative form
of cyclin D1 in the ES cells abrogated the Notch-induced
proliferative ability, and, conversely, a constitutively active
form of cyclin D1 mimicked the effect of Notch on cell pro-
liferation [96]. Gifitinib-acquired resistant lung cancer cells
displayed EMT phenotype. Molecular analyses confirmed
that activation of Notch-1 and its target genes, which in-
duced expression of mesenchymal marker vimentin, snail
and hes-1, and decreased epithelial marker E-cadherin. The
elevated expression of Notch-1 could directly suppress p21
Waf1/Cipl accompanied with the increasing of cyclin D1,
giving rise to the EMT phenotype. Meanwhile, knockdown
of Notch-1 decreased cyclinD1 expression and reversed
EMT. These findings suggest that the aggressive behavior
caused by cyclinD1 might be driven by the mis-expression
of Notch pathway in NSCLC, which finally down regulates
p21 Waf1/Cipl and promotes the EMT phenotype [71].
Targeting Notch signaling in NSCLC
In vivo evidence that Notch inhibitor is a potential thera-
peutic agent came from Kras(G12V)-driven NSCLCs micemodel. Pharmacologic treatment of mice carrying autoch-
thonous NSCLCs with a γ-secretase inhibitor (GSI)
blocked cancer growth. Correspondingly, molecular ana-
lysis of treated cancer tissues demonstrated reduced HES1
levels and phosphorylated ERK [97]. Currently, several
classes of investigational Notch inhibitors have been de-
veloped. These include monoclonal antibodies against
Notch receptors or ligands, decoys to soluble forms of the
extracellular domain of Notch receptor or Notch ligands,
blocking peptides, and gamma-secretase inhibitors (GSIs)
or natural compounds [98].
At present, GSIs are the most extensively explored.
RO4929097, a small-molecule inhibitor of GSI with high
oral bioavailability and is a potent and selective inhibitor
of gamma-secretase, has been tested in phase I study in
refractory metastatic or locally advanced solid tumors
[99], and phase II studies for metastatic melanoma [100],
metastatic colorectal cancer [101] and metastatic pancre-
atic adenocarcinoma [102]. Another GSIs, PF-03084014,
was also evaluated on phase I in advanced solid tumor
[103]. In preclinical study, MRK-003 was evaluated in
triple negative breast cancer cells by MRK-003 alone and
in combination with paclitaxel. Immunohistochemical
staining for activated NOTCH1 and HES4 expression
could be molecular biomarkers, identifying solid tumors
that are likely to respond to GSI-based therapies [104].
Preclinical study of MRK-003 in pancreatic cancer [105]
and in multiple myeloma and non-Hodgkin’s lymphoma
exhibited promising activity [106]. Treatment with GSIs
MK-0752 in breast cancer cell lines reduced stem cell sub-
population in vitro and in human tissues from clinical trial
[107]. Clinical benefit of MK-0752 in adult patients with
advanced solid tumors was observed with well tolerated
toxicity in Phase I study, therefore promoting to combin-
ational trials [108].
Inhibitors of Notch signaling can be used not only as
direct anti-cancer agents but also as a sensitizer to current
therapy. Platinum-based chemotherapy is the first-line
treatment for NSCLC, but recurrence occurs in most pa-
tients. Experimental study found that treatment of NSCLC
cell line H460 and H661 enriched CD133 (+) cells and
upregulated ABCG2 and ABCB1 expression, which con-
ferred the cross-resistance to doxorubicin and paclitaxel.
Detailed molecular analysis found that the enrichment of
CD133 (+) cells by cisplatin depended on Notch signaling.
Moreover, pretreatment with the γ-secretase inhibitor
or Notch1 short hairpin RNAs (shRNA) remarkably in-
creased the sensitivity to doxorubicin and paclitaxel. Im-
portantly, similar phenomena were observed both in
engrafted tumors derived from transplanted animal model
and the relapsed tumors of patients who had received cis-
platin treatment [109]. Gamma-secretase inhibitor DAPT
alone slightly inhibited the proliferation and exhibited lit-
tle effect on the cell cycle, but enhanced the inhibitory
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Interestingly, this effect was especially significant in
CD133 (+) cells, suggesting that Notch pathway blockade
may be a useful CSC-targeted therapy in lung cancer
[110]. In complementary, Dr. Carbone’s group found that
treatment of EGFR-mutated lung cancer cell lines with er-
lotinib enriched the ALDH+ stem-like cells with stem-like
cell potential through EGFR-dependent activation of
Notch3. Moreover, γ secretase inhibitor could reverse this
phenotype. At molecular level, physical association be-
tween the Notch3 and EGFR receptors leads to tyrosine
phosphorylation of Notch3. This study could explain the
unflavored survival observed in some studies of erloti-
nib treatment at early-stage disease, and imply that
specific dual targeting might overcome adverse effect
of TKIs [111].
γ-Secretase inhibitor administration after radiation had
the greatest growth inhibition of lung cancer in vitro
and in vivo. Mechanically, enhanced apoptosis of lung
cancer cell lines in combination group were through
regulation of MAPK and Bcl-2 family proteins. Further-
more, radiation-induced activation of Notch was blocked
by GSI administration, suggesting that treatment with
GSI could prevent Notch-induced radiation resistance
[112]. Together, above studies provided compelling evi-
dence for exploiting Notch inhibitors in clinic trial. In
most cases, the application of GSI is limited because of
gut toxicity and goblet cell hyperplasia. Therefore, the
best dose and schedule need to be optimized.
Other receptor-specific approaches like siRNA directed
against Notch might be useful in reducing the tumorigen-
icity and invasive of NSCLC. For instance, nanoparticle
(NP) technology has been applied to deliver specific
siRNA to knockdown Notch1 to arrest tumor growth and
reverse EMT by the up-regulation of miR-200a and down-
regulation of the transcription factors ZEB1, ZEB2, Snail
and Slug [113]. Furthermore, monoclonal antibody against
Notch can also reduce the invasion of NSCLC [114,115].
The complex of γ-secretase is a transmembrane protease
that catalyses the cleavage of a set of membrane proteins
and is comprised of four subunits encoded by four genes,
including PSEN1, PSENEN, NCSTN and APH1. Targeting
NCSTN using specific mAbs may represent a novel mode
of treatment for invasive triple-negative breast cancer, for
which there are few targeted therapeutic options. It is sug-
gested that measuring NCSTN in patient samples may
serve as a molecular marker for anti-NCSTN therapy in
the clinic [116].
>Some natural agents such as curcumin, 3,3′-diindo-
lylmethane (DIM), resveratrol, and epigallocatechin-3-
gallate (EGCG) have been reported to be effective on
targeting Notch signaling, suggesting they can also be
promising alternative strategies for NSCLC chemother-
apy [117,118].Conclusion
As a well known driving force of cell invasion, migration
and metastasis, EMT has been shown to induce resist-
ance of cancer cells to conventional chemotherapy and
radiotherapy. Notch signaling not only activates cell pro-
liferation, antagonize apoptosis but also cross-talks with
several transcriptional factors to promote EMT, leading
to enhanced motility in vitro and invasion and metasta-
sis in vivo. Theoretically, combination of chemotherapy
or radiotherapy with Notch inhibitors might acquire
synergistic effect and improve chemotherapy response.
Although promising results have been noticed in some
patients with Notch inhibitors in clinical trials, stratifica-
tion biomarkers to identify patients who are most likely
benefit from GSIs treatment are required for a successful
development of this class of drugs.
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